East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Lacosamide Oral Solution USP, 10 mg/mL. Aurobindo Pharma’s Lacosamide Oral Solution, are an AB-rated generic equivalent to the reference listed drug (RLD), VIMPAT® Oral Solution manufactured by UCB, Inc.

Lacosamide Oral Solution are indicated in:

• Patients 17 years and older with partial-onset seizures as monotherapy or adjunctive therapy.